Omeros Corporation (OMER) Financial Analysis & Valuation | Quarter Chart
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compu... more
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercia... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $1.20B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Gregory A. Demopulos |
| IPO Date | 2009-10-08 | CAGR | — |
| Employees | 175 | Website | www.omeros.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.04% | Total Yield | 0.04% |
OMER chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $711.52M | P/E | 7.6 | Forward P/E | 13.47 | PEG | — |
| P/S | 784.28 | P/B | -585.17 | P/CF | -437.07 | P/FCF | -438.47 |
| Sales | $38.42M | Sales 1Y | inf% | Sales 3Y | inf% | Sales 5Y | 4.56% |
| EPS | $2.18 | EPS 1Y | -181.52% | EPS 3Y | 168.75% | EPS 5Y | -175.11% |
| Sales QoQ | 188.38% | EPS QoQ | -75.81% | Sales QoQ Avg | — | EPS QoQ Avg | -131.24% |
| Gross Margin | 95.77% | Operating Margin | -189.53% | Profit Margin | 324.88% | ROCE | -37.95% |
| ROA | 44% | ROE | -109% | Altman Z Score | -0.02 | Piotroski Score | 6 |
| Current Ratio | 1.95 | Quick Ratio | 1.94 | Cash Ratio | 0.02 | Op. CF Ratio | 0.04 |
| Debt/Equity | -1.63 | Debt/Assets | 0.29 | Lt Debt/Equity | -0.89 | Lt Debt/Cap. | -4.51 |
| Intrst Cov. | -3.28 | Inventory Turnover | 1.93 | Asset Turnover | 0.13 | Receivables Turnover | 1.8 |
| Enterprise Value | $711.52M | P/E Ratio | 7.6 |
| Forward P/E | 13.47 | PEG Ratio | — |
| P/S Ratio | 784.28 | P/B Ratio | -585.17 |
| P/CF Ratio | -437.07 | P/FCF Ratio | -438.47 |
| EPS | $2.18 | EPS Growth 1Y | -181.52% |
| EPS Growth 3Y | 168.75% | EPS Growth 5Y | -175.11% |
| Revenue Growth 1Y | inf% | Gross Margin | 95.77% |
| Operating Margin | -189.53% | Profit Margin | 324.88% |
| ROE | -109% | ROA | 44% |
| ROCE | -37.95% | Current Ratio | 1.95 |
| Quick Ratio | 1.94 | Cash Ratio | 0.02 |
| Debt/Equity | -1.63 | Interest Coverage | -3.28 |
| Altman Z Score | -0.02 | Piotroski Score | 6 |
Omeros Corporation (OMER) valuation & financials
Omeros Corporation (OMER) has a market capitalization of $1.20B and trades at a price-to-earnings ratio of 7.6. It operates in the Healthcare sector (Biotechnology).
Omeros Corporation's revenue grew — over the last year.
Omeros Corporation's next earnings report is scheduled for November 12, 2026 (provider scheduled date); analysts estimate EPS of $0.03. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)